On September 23, 2024 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM) (Press release, Ideaya Biosciences, SEP 22, 2024, View Source [SID1234646788]). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The investor webcast presentation agenda to review the interim Phase 2 clinical data and regulatory update for darovasertib in neoadjuvant UM will be the following:
Market introduction: annual incidence of UM
Registrational trial design based on FDA Type C meeting guidance
Phase 2 clinical data update
Baseline characteristics
AE profile
Clinical efficacy from Phase 2 company-sponsored and IST
The investor webcast and conference call will include participation from a key opinion leader. IDEAYA management, Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences, and Darrin Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences, will also serve as presenters. The link to the investor webcast will be available on the Investor Relations Events section of the Company’s website at: View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source." target="_blank" title="View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source." rel="nofollow">View Source Registration is available at View Sourceevents" target="_blank" title="View Sourceevents" rel="nofollow">View Source or View Source in advance of the event.
IDEAYA’s darovasertib investor webcast presentation, as well as an updated corporate presentation, which will incorporate the updated darovasertib clinical data and regulatory update, will be available on the company’s website, at its Investor Relations portal (View Source) at approximately 8:00 am ET on Monday, September 23, 2024.